CLINICAL_TRIALS
trial_result
· 2025-02-17
Clinical Trial Update: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) [Phase 1]
Summary
Phase 1 renal impairment study of MK-0616 (Enlicitide Decanoate), an oral PCSK9 inhibitor, in hypercholesterolemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolaemia | Phase 1 | Status: COMPLETED | Results posted: 2025-02-17